Alaunos Therapeutics, Inc. (TCRT) stock
TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.66+0.06 (+3.75%)
Close on Nov 17, 2026Market cap $4.22MP/E –Yield –
Alaunos Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Alaunos Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.65M. For fiscal 2025 it was $1.36M, up 276.5% from the year before. Over ten years it grew -35.3% a year on average. The highest annual figure on record is $157.79M in fiscal 2016.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.36M | +276.5% |
| FY2024 | Dec 31, 2024 | $362.00K | -97.8% |
| FY2023 | Dec 31, 2023 | $16.28M | -34.9% |
| FY2022 | Dec 31, 2022 | $25.02M | -49.6% |
| FY2021 | Dec 31, 2021 | $49.64M | -5.8% |
| FY2020 | Dec 31, 2020 | $52.70M | +37.5% |
| FY2019 | Dec 31, 2019 | $38.33M | +12.3% |
| FY2018 | Dec 31, 2018 | $34.13M | -24.3% |
| FY2017 | Dec 31, 2017 | $45.08M | -71.4% |
| FY2016 | Dec 31, 2016 | $157.79M | +47.8% |
| FY2015 | Dec 31, 2015 | $106.79M | +226.5% |
| FY2014 | Dec 31, 2014 | $32.71M | -23.7% |
| FY2013 | Dec 31, 2013 | $42.85M | -48.6% |
| FY2012 | Dec 31, 2012 | $83.45M | +46.2% |
| FY2011 | Dec 31, 2011 | $57.08M | +342.2% |
| FY2010 | Dec 31, 2010 | $12.91M | +183.4% |
| FY2009 | Dec 31, 2009 | $4.56M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $388.00K | +109.7% |
| Q1 FY2026 | Mar 31, 2026 | $427.00K | +23.1% |
| Q4 FY2025 | Dec 31, 2025 | $361.00K | +152.4% |
| Q3 FY2025 | Sep 30, 2025 | $469.00K | +160.6% |
| Q2 FY2025 | Jun 30, 2025 | $185.00K | +46.8% |
| Q1 FY2025 | Mar 31, 2025 | $347.00K | -62.8% |
| Q3 FY2024 | Sep 30, 2024 | $143.00K | -96.1% |
| Q2 FY2024 | Jun 30, 2024 | $180.00K | -96.5% |
| Q1 FY2024 | Mar 31, 2024 | $126.00K | -98.1% |
| Q4 FY2023 | Dec 31, 2023 | $933.00K | -83.4% |
| Q3 FY2023 | Sep 30, 2023 | $3.66M | -53.7% |
| Q2 FY2023 | Jun 30, 2023 | $5.19M | -12.6% |
| Q1 FY2023 | Mar 31, 2023 | $6.50M | +16.6% |
| Q4 FY2022 | Dec 31, 2022 | $5.61M | -31.8% |
| Q3 FY2022 | Sep 30, 2022 | $7.89M | -70.7% |
| Q2 FY2022 | Jun 30, 2022 | $5.94M | -57.5% |
| Q1 FY2022 | Mar 31, 2022 | $5.58M | -60.1% |
| Q4 FY2021 | Dec 31, 2021 | $8.22M | -31.8% |
| Q1 FY2021 | Jun 30, 2021 | $26.91M | +111.8% |
| Q4 FY2020 | Dec 31, 2020 | $13.97M | +36.8% |
| Q3 FY2020 | Sep 30, 2020 | $13.97M | +61.6% |
| Q2 FY2020 | Jun 30, 2020 | $12.05M | +20.5% |
| Q1 FY2020 | Mar 31, 2020 | $12.71M | +34.1% |
| Q4 FY2019 | Dec 31, 2019 | $10.22M | +24.6% |
| Q3 FY2019 | Sep 30, 2019 | $8.64M | +4.6% |
| Q2 FY2019 | Jun 30, 2019 | $10.00M | +33.5% |
| Q1 FY2019 | Mar 31, 2019 | $9.48M | -6.9% |
| Q4 FY2018 | Dec 31, 2018 | $8.20M | -26.7% |
| Q3 FY2018 | Sep 30, 2018 | $8.26M | -25.6% |
| Q2 FY2018 | Jun 30, 2018 | $7.49M | -30.9% |
| Q1 FY2018 | Mar 31, 2018 | $10.18M | -14.9% |
| Q4 FY2017 | Dec 31, 2017 | $11.18M | +19.1% |
| Q3 FY2017 | Sep 30, 2017 | $11.11M | +23.7% |
| Q2 FY2017 | Jun 30, 2017 | $10.83M | -91.6% |
| Q1 FY2017 | Mar 31, 2017 | $11.97M | – |
| Q4 FY2016 | Dec 31, 2016 | $9.39M | – |
| Q3 FY2016 | Sep 30, 2016 | $8.98M | – |
| Q2 FY2016 | Jun 30, 2016 | $129.23M | – |
See a number that looks wrong?